CBL and lung carcinoma: Among the EGFR‐interacting proteins identified, ERBB2, though mutated or overexpressed in 2%–5% of lung cancers, is already an established target, making it less compelling for novel drug development.[22] GRB2, SHC1, and CBL are cytoplasmic proteins without significant overexpression in lung cancer, limiting their therapeutic potential.